IgM Immunoglobulin Purification for Virus Safety and Storage Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing IgM-containing immunoglobulin compositions for intravenous administration are ineffective in inactivating or removing non-enveloped viruses and proteolytic activity, leading to potential safety risks and instability during long-term storage, while maintaining high yields and native IgM activity.
Innovation Solution
A process involving the use of a vibrating agitator during octanoic acid treatment to precipitate contaminants, followed by filtration and additional steps like mild acid treatment and UVC irradiation, enhances virus safety and stability without chemical modification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional virus inactivation methods (UVC irradiation, chemical treatments) are used, then virus safety is improved, but IgM activity and yield are reduced
Solution Approach 1:
The patent applies preliminary action by performing octanoic acid treatment before virus inactivation steps. This preliminary purification removes contaminants that would otherwise require more aggressive virus inactivation methods, thereby preserving IgM activity while still achieving virus safety. The octanoic acid treatment is performed as a preparatory step that simplifies subsequent processing.
Solution Approach 2:
Octanoic acid serves as an intermediary substance that facilitates the separation of contaminants from immunoglobulins. The acid treatment creates intermediate complexes with contaminating proteins and lipids, allowing their removal while leaving the immunoglobulins intact. This intermediary approach enables gentle purification without requiring harsh virus inactivation conditions.
2Quantity of substance
If IgM is enriched in the preparation, then therapeutic efficacy is improved, but stability and aggregation are worsened
Solution Approach 1:
The patent applies the extraction principle by selectively removing contaminants (proteases, denatured proteins, lipids) that cause aggregation and instability. The octanoic acid treatment extracts these harmful components while preserving the enriched IgM. This selective removal allows high IgM concentration to be maintained without the destabilizing effects of contaminants.
Solution Approach 2:
The patent employs parameter changes by adjusting pH and temperature conditions during octanoic acid treatment to optimize both IgM enrichment and stability. The treatment conditions are carefully controlled to prevent IgM aggregation while removing contaminants. Temperature is maintained at 20-37°C and pH is adjusted to facilitate selective precipitation of contaminants without affecting IgM stability.
3Reliability
If multiple virus inactivation steps are added, then virus safety is improved, but process complexity and cost are increased
Solution Approach 1:
The patent merges the purification function with the virus safety function by combining octanoic acid treatment (which removes contaminants) with subsequent mild virus inactivation steps. This combined approach achieves both purification and virus safety in an integrated process flow, reducing the need for separate, complex treatment steps. The process consolidates multiple functions into a streamlined sequence.
Solution Approach 2:
The octanoic acid treatment step serves multiple functions simultaneously: it purifies the immunoglobulin solution by removing contaminants, prepares the solution for subsequent processing, and reduces the burden on later virus inactivation steps. This multi-functional approach simplifies the overall process while maintaining high virus safety standards.
4Ease of manufacture
If proteases are not removed, then process simplicity is maintained, but product stability and tolerability are reduced
Solution Approach 1:
The patent applies preliminary action by removing proteases through octanoic acid treatment before final product formulation. This preliminary removal of proteolytic activity prevents subsequent degradation of immunoglobulins during storage and handling, ensuring long-term stability without requiring complex stabilization measures later in the process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high yields of chemically unmodified, virus-safe IgM with low proteolytic activity, maintaining stability for over 12 months in liquid form and effective against both enveloped and non-enveloped viruses.
Implementation Method 1
mixing a C 7 to C 9 carboxylic acid with the solution and treating the mixed solution with a vibrating agitator to precipitate contaminating proteins
Implementation Method 2
treating the mixed solution with a vibrating agitator to precipitate contaminating proteins
Implementation Method 3
mild acid conditions and UVC irradiation, enhances virus safety and stability
Data Source
Figure 1
AI summary
Provided is a process for the preparation of an immunoglobulin composition from a plasma comprising immunoglobulins, and antibody preparations prepared utilizing the process.